Menu Back to Biosimilars-Conference


September 20-21: Conference

The Biosimilars Price Competition and Innovation Act (BCPIA) created a biosimilars approval pathway in the US with the goal of increasing access to safe, effective, and cost effective biological treatment options for patients. To date, significant progress has been made in the science and regulation of biosimilar development and approval but barriers still exist to a robust biosimilars market. The current ongoing challenges are legal complications to the launch of a biosimilar, the persistence of misinformation and disparagement, and delays in the creation of policies that increase patient access. The challenges have been and continue to be complex, interrelated, and best addressed by stakeholder collaboration, not only within the US but across global regions.

Biosimilars remain of interest due to for their potential to provide cost savings to patients, reducing overall burden on the system, and possible improvement over the competition. To increase their market share, stakeholders are now focusing on streamlining biosimilars development, meeting ongoing manufacturing challenges, addressing pricing issues, and educating prescriber and patients on the benefits of biosimilars. At the DIA 2022 Biosimilars Conference, manufacturers, regulators, payers, prescribers, and patients will come together to discuss factors that influence biosimilar development and access and to share perspectives on what success and equilibrium will look like. They’ll apply the newest thinking and relevant learnings from global regions to build strategies for continuing the growth of the biosimilars market and bringing these important biologic therapies – and cost savings - to patients.

While we develop our 2022 Agenda, please take a look at the 2021 final agenda

Social distancing measures may be in place at the time of the event. Therefore, we encourageyou to register and make your housing arrangements early due to potential limited capacity. Don’t miss out on your chance to meet live again with your friends and colleagues!

Who should attend?

Professionals involved in:
  • Biosimilar/Biologic Pharmaceutical Research
  • Biomedical Product Development and Manufacturing
  • Chemistry, Manufacturing and Controls
  • Regulatory Affairs
  • Clinical and Nonclinical Research
  • Biostatistics and Data Management
  • Business Development
  • Marketing and Commercialization for biosimilars
  • Medical Communications/MSLs
  • Patient Advocacy/Patient Support Programs
  • Health and medical care across therapeutic disciplines
  • Health Education
  • Provision of prescription products
  • Development and management of prescription product formularies
  • Development and management of prescription benefit plans
  • Quality management

Program Committee

  • Leah  Christl, PhD
    Leah Christl, PhD Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
    Amgen, United States
  • Tiffany  Fletcher, MA
    Tiffany Fletcher, MA Head of Global Access Policy
    Viatris, United States
  • Denis  Arsenault, MA
    Denis Arsenault, MA Manager, Policy Development
    Health Canada, Canada
  • Mauricio  Ede, MD, PhD
    Mauricio Ede, MD, PhD Chief Medical & Scientific Officer
    Sandoz Canada Inc., Canada
  • Julie  Marechal-Jamil, MSc
    Julie Marechal-Jamil, MSc Director, Biosimilar Policy and Science
    Medicines For Europe, Belgium
  • Stanton  Mehr
    Stanton Mehr Director of Content
    Biosimilars Review & Report, United States
  • Juliana Marguerite Reed, MS
    Juliana Marguerite Reed, MS Executive Director
    The Biosimilars Forum, United States
  • Laura D. Wingate
    Laura D. Wingate Executive Vice President, Education, Support, and Advocacy
    Crohn's & Colitis Foundation, United States
  • Stacey  Ricci, DrSc
    Stacey Ricci, DrSc Director, Scientific Review Staff, OTBB, OND, CDER
    FDA, United States
  • Representative Invited
    Representative Invited DIA, United States
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions